The results of the trial will be announced after unblinding the data in the first quarter of 2008. Previously, the FDA had granted Fast Track status to Sybryx. Results of a previous Phase IIa trial demonstrated that Sybryx relieved the symptoms of chronic sinusitis in post-surgical patients.
Robin Campbell, president and CEO of Naryx Pharma, said: “We are pleased that we have completed this milestone in the development of Sybryx and would like to thank all of the investigators who are participating in the trial. Many patients are suffering from chronic sinusitis, and we look forward to continuing to develop a treatment for this serious and sometimes debilitating disease.”